Silk Road Medical Reports Second Quarter 2022 Financial Results
SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022.
“We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility,” said Erica Rogers, CEO of Silk Road Medical. “We also gained meaningful market share through strong physician utilization as we continue to establish TCAR as the minimally-invasive standard of care in stroke prevention, evidenced by recently eclipsing 50,000 global TCAR procedures.”
Second Quarter 2022 Financial Results
Revenue for the second quarter of 2022 was $33.2 million, an increase of $6.7 million, or 25%, compared to the second quarter of 2021. Growth was driven primarily by increased TCAR adoption.
Gross profit for the second quarter of 2022 was $24.2 million compared to $19.9 million for the second quarter of 2021. Gross margin for the second quarter of 2022 was 73% compared to 75% for the second quarter of 2021. Gross margin was primarily impacted by continued manufacturing expansion costs at our new Minnesota facility.
Operating expenses were $38.4 million for the second quarter of 2022, compared to $29.8 million in the comparable prior year period, which represents an increase of 29%. The increase was driven by increased headcount in our commercial and R&D organizations, along with continued investments in new and ongoing R&D programs.
Net loss was $15.4 million in the second quarter of 2022, or $0.44 per share, as compared to a loss of $10.5 million, or $0.31 per share, in the corresponding period of the prior year.
Cash, cash equivalents and short-term investments were $108.9 million as of June 30, 2022.
2022 Financial Guidance
Silk Road Medical projects revenue for the full year 2022 to range from $128 million to $133 million, which represents 26% to 31% growth over the company’s prior year revenue.
Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, progress made on achieving our corporate goals, and the overall strength of our business. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our filing made with the Securities and Exchange Commission in Silk Road’s Quarterly Report on Form 10-Q filing made with the Securities and Exchange Commission on May 10, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Silk Road Medical disclaims any obligation to update these forward-looking statements.
Lynn Lewis or Marissa Bych
Silk Road Medical
|SILK ROAD MEDICAL, INC.|
|Statements of Operations Data|
|(unaudited, in thousands, except share and per share data)|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Cost of goods sold||9,012||6,598||17,588||12,137|
|Research and development||10,655||7,261||18,778||12,744|
|Selling, general and administrative||27,700||22,549||54,975||43,743|
|Total operating expenses||38,355||29,810||73,753||56,487|
|Loss from operations||(14,194||)||(9,952||)||(30,148||)||(20,115||)|
|Loss on debt extinguishment||(245||)||—||(245||)||—|
|Other income (expense), net||(50||)||(6||)||(166||)||(10||)|
|Other comprehensive loss:|
|Change in unrealized gain (loss) on investments, net||(2||)||(3||)||(2||)||(36||)|
|Net change in other comprehensive loss||(2||)||(3||)||(2||)||(36||)|
|Net loss and comprehensive loss||$||(15,400||)||$||(10,542||)||$||(32,079||)||$||(21,269||)|
|Net loss per share, basic and diluted||$||(0.44||)||$||(0.31||)||$||(0.91||)||$||(0.62||)|
|Weighted average common shares used to compute net loss per share, basic and diluted||35,143,178||34,534,099||35,083,569||34,435,812|
|SILK ROAD MEDICAL, INC.|
|Balance Sheets Data|
|(unaudited, in thousands)|
|June 30, 2022||December 31, 2021|
|Cash and cash equivalents||$||87,637||$||110,231|
|Accounts receivable, net||15,779||11,832|
|Prepaid expenses and other current assets||4,653||3,412|
|Total current assets||146,919||143,326|
|Property and equipment, net||9,755||7,697|
|Other non-current assets||5,815||5,370|
Liabilities and stockholders' equity
|Total current liabilities||21,241||26,086|
|Preferred stock, $0.001 par value||—||—|
|Common stock, $0.001 par value||35||35|
|Additional paid-in capital||380,775||367,907|
|Accumulated other comprehensive income||(2||)||—|
|Total stockholders' equity||60,029||79,240|
|Total liabilities and stockholders' equity||$||162,721||$||156,625|